200 Participants Needed

Alectinib + Crizotinib for Cancer

Recruiting at 33 trial locations
RS
Overseen ByReference Study ID Number: BO39694 www.roche.com/about_roche/roche_worldwide.htm
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Hoffmann-La Roche
Must be taking: Alectinib, Crizotinib
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.

Will I have to stop taking my current medications?

The trial requires that you do not take strong cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days before starting and during treatment with crizotinib. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug combination Alectinib and Crizotinib for cancer?

Alectinib has been shown to be effective in treating advanced ALK-positive non-small cell lung cancer (NSCLC), especially in patients who have not responded to Crizotinib. Studies have demonstrated that Alectinib improves progression-free survival and has a good safety profile, making it a promising option for patients with this type of cancer.12345

Is the combination of Alectinib and Crizotinib safe for humans?

Alectinib and Crizotinib have been studied for safety in patients with ALK-positive non-small-cell lung cancer. Alectinib generally has a manageable safety profile, with most side effects being mild or moderate, such as liver issues and reduced white blood cell counts. Crizotinib has been compared to Alectinib, with Alectinib showing a favorable safety profile.15678

How is the drug combination of Alectinib and Crizotinib unique for cancer treatment?

The combination of Alectinib and Crizotinib is unique because Alectinib is a highly selective ALK inhibitor that has shown improved progression-free survival and better central nervous system outcomes compared to Crizotinib alone in ALK-positive non-small cell lung cancer (NSCLC). This combination may offer enhanced efficacy, especially for patients with brain metastases.1591011

Research Team

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Eligibility Criteria

This trial is for patients with ALK- or RET-positive cancer who were part of a previous Roche-sponsored alectinib study and are still benefiting from alectinib or crizotinib. They must not be able to switch to commercial supply, agree to contraception if necessary, and cannot join if they're pregnant, breastfeeding, had no benefit in the parent trial, experienced severe side effects that led to discontinuation, or have unresolved serious adverse events.

Inclusion Criteria

I agree to use effective birth control or remain abstinent during and for 3 months after treatment.
I am benefiting from alectinib or crizotinib in a Roche trial but can't switch to commercial supply.
For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug
See 1 more

Exclusion Criteria

I don't have any severe side effects from previous treatments that haven't improved.
I stopped taking alectinib or crizotinib before starting the new study drug.
I had to stop my cancer treatment for over 3 weeks because of side effects, but now I'm better or stable.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive continued treatment with alectinib or crizotinib as applicable, following the same dose and schedule as in the parent trial

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Alectinib
  • Crizotinib
Trial Overview The study continues treatment with either alectinib or crizotinib for participants previously enrolled in related trials. It aims to provide these drugs when commercial options aren't available and assess long-term benefits and safety for those still showing improvement.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: CrizotinibExperimental Treatment1 Intervention
Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
Group II: AlectinibExperimental Treatment1 Intervention
Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.

Alectinib is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Alecensa for:
  • Metastatic ALK-positive non-small cell lung cancer (NSCLC)
  • Adjuvant treatment following tumor resection in patients with ALK-positive NSCLC
🇪🇺
Approved in European Union as Alecensa for:
  • Metastatic ALK-positive non-small cell lung cancer (NSCLC)
  • Adjuvant treatment following tumor resection in patients with ALK-positive NSCLC

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Findings from Research

Alectinib is an effective first-line treatment for adults with advanced ALK-positive non-small cell lung cancer (NSCLC), showing significantly improved progression-free survival compared to crizotinib and chemotherapy in clinical trials lasting up to 19 months.
The drug has a manageable safety profile, with most side effects being mild to moderate, making it a recommended option in treatment guidelines for patients with advanced ALK-positive NSCLC.
Alectinib: A Review in Advanced, ALK-Positive NSCLC.Paik, J., Dhillon, S.[2019]
Alectinib is a highly selective ALK inhibitor that has shown effectiveness against most crizotinib resistance mutations and has a favorable safety profile, making it a promising treatment for ALK-positive non-small-cell lung cancer (NSCLC).
The Phase III J-ALEX study demonstrated that alectinib significantly improves progression-free survival compared to crizotinib in treatment-naive ALK-positive NSCLC patients, suggesting it may become the preferred first-line therapy for this condition.
Alectinib for treatment of ALK-positive non-small-cell lung cancer.Avrillon, V., Pérol, M.[2022]
Alectinib is a highly effective treatment for ALK fusion-gene positive advanced non-small cell lung cancer (NSCLC), with a 93.5% objective response rate in a phase 1-2 study involving ALK inhibitor-naive patients.
The drug is well tolerated, showing no grade 4 adverse events, and has a promising safety profile, with a 76% two-year progression-free survival rate and no progression of CNS lesions in patients with known metastases during treatment.
Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.McKeage, K.[2022]

References

Alectinib: A Review in Advanced, ALK-Positive NSCLC. [2019]
Alectinib for treatment of ALK-positive non-small-cell lung cancer. [2022]
Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer. [2022]
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). [2023]
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis. [2022]
Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis. [2022]
Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan. [2021]
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. [2020]
Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study. [2022]
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security